Trials / Withdrawn
WithdrawnNCT03452267
Insulin Signaling in Skeletal Muscle
Effect of Metformin and Pioglitazone on Insulin Signaling in Skeletal Muscle
- Status
- Withdrawn
- Phase
- Phase 2 / Phase 3
- Study type
- Interventional
- Enrollment
- 0 (actual)
- Sponsor
- Wayne State University · Academic / Other
- Sex
- All
- Age
- 18 Years – 60 Years
- Healthy volunteers
- Not accepted
Summary
The insulin sensitizing effects of metformin and pioglitazone in the skeletal muscle remain unknown. Our group aims to analyze molecular changes within the skeletal muscle of pre-diabetic patients through the use of a clinical trial in humans.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Metformin | oral, 850 mg twice daily |
| DRUG | Pioglitazone | oral, 45 mg daily |
| DRUG | Placebo | oral, once daily |
Timeline
- Start date
- 2019-09-01
- Primary completion
- 2024-12-01
- Completion
- 2025-06-01
- First posted
- 2018-03-02
- Last updated
- 2020-10-08
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT03452267. Inclusion in this directory is not an endorsement.